Glucagon-like peptide-1 receptor agonists as adjunctive therapy in refractory hypertriglyceridemia following recurrent pancreatitis
Abstract
A 39-year-old Chinese man was first evaluated at a multidisciplinary metabolic dysfunction-associated liver disease clinic following 6 episodes of hypertriglyceridemia-induced pancreatitis over 9 years despite maximal therapy with statins, fibrates, and omega-3 fatty acids. Peak triglycerides reached 2329 mg/dL (Système International [SI]: 26.3 mmol/L; reference range, <177 mg/dL [SI: <2 mmol/L]). Comorbidities included poorly controlled diabetes, recurrent hypoglycemia, and steatotic liver disease with moderate fibrosis. Despite historical safety concerns regarding glucagon-like peptide-1 receptor agonists in prior pancreatitis, semaglutide was cautiously initiated. This achieved sustained triglyceride normalization to 213 mg/dL (SI: 2.4 mmol/L), weight loss, glycemic improvement, hypoglycemia resolution, improved liver elastography parameters, and insulin cessation without pancreatitis recurrence. This case demonstrates that glucagon-like peptide-1 receptor agonists warrant consideration in treatment-resistant hypertriglyceridemia with prior pancreatitis when conventional therapy fails, challenging traditional contraindications in carefully selected patients under multidisciplinary care.
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.